Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
about
Activities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophagesSerum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.Developmental pharmacokinetic changes of Lamivudine in infants and childrenPopulation pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infantsRecommendations in pediatric antiretroviral therapy.Antiretroviral bioanalysis methods of tissues and body biofluids.Lamivudine for the treatment of HIV.Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.CSF penetration by antiretroviral drugs.Pharmacokinetic considerations in the use of antivirals in neonates.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.Age-dependent pharmacokinetics of lamivudine in HIV-infected children.
P2860
Q28343822-BA09210E-17EB-4329-BFAC-C55888BBA5CDQ33703360-286777D0-F69B-430F-BBDD-2AD3B3A08E67Q33976456-B35AFA4F-90F0-42FC-B47D-659CF3885972Q33978917-71F64B84-755A-40A8-859D-C47AF7BD4838Q34339657-A2B0D190-35D1-4FEC-BF0E-02CD2C806AC5Q34544211-D45E0474-94CB-436B-9361-1BFEF24674E6Q36013430-2038D199-1775-4A80-8C80-AABDFB1E6C62Q36313247-153C2D22-7BE4-41F7-9EFA-911D72DAC518Q36719674-29E41946-8BBB-455B-AC49-F6C6CBBDABCCQ37332868-F63EEB2A-B629-4B83-AC82-0947BB26B3F1Q37650410-383A63A5-08B3-416F-9B02-06ECBC36CA08Q37731863-30AF87ED-A6CD-4C25-9EEA-8B0DE48F63C6Q37835819-BE628DA6-4E1A-49D5-8ED3-1CD21DE51E0CQ38060571-663A7957-4DAA-4487-B33F-F85D9ED943B8Q38624965-00C227B4-4C1A-4BBB-8BF9-F593AD99301FQ38771392-926BDD38-C5F5-495B-B726-796C6A44EB39Q38868724-0B153B7E-3847-41CE-903A-EF315B2B23D4Q42625394-52001CF5-44AB-44E7-8CF6-7DC03A6AFC20Q50695249-9EB83FF1-254A-4C41-82A6-3A9F05249715
P2860
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Lamivudine in children with hu ...... eficiency Virus Working Group.
@en
type
label
Lamivudine in children with hu ...... eficiency Virus Working Group.
@en
prefLabel
Lamivudine in children with hu ...... eficiency Virus Working Group.
@en
P2093
P356
P1476
Lamivudine in children with hu ...... eficiency Virus Working Group.
@en
P2093
Brouwers P
Goldsmith J
P356
10.1093/INFDIS/174.1.16
P407
P577
1996-07-01T00:00:00Z